| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1989PNAS...86.7585F |
| P356 | DOI | 10.1073/PNAS.86.19.7585 |
| P932 | PMC publication ID | 298110 |
| P698 | PubMed publication ID | 2508092 |
| P5875 | ResearchGate publication ID | 20648234 |
| P2093 | author name string | D J Fitzgerald | |
| G A Fitzgerald | |||
| P2860 | cites work | Thrombin activity of fibrin thrombi and soluble plasmic derivatives | Q72788151 |
| [Rapid physiological coagulation method in determination of fibrinogen] | Q74515389 | ||
| Isolation and characterization of a high molecular weight glycoprotein from human blood platelets | Q22009134 | ||
| Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo | Q34521034 | ||
| Interaction of coagulation factor Xa with human platelets | Q35053163 | ||
| Protection of factor Xa from neutralization by the heparin-antithrombin complex | Q35207027 | ||
| Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis | Q35593380 | ||
| Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin | Q35807759 | ||
| Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs | Q35812008 | ||
| Tissue plasminogen activator | Q39605345 | ||
| Thrombolytic therapy: current status (1). | Q39640542 | ||
| Thrombin active-site regions | Q39746923 | ||
| Thromboxane a2: biosynthesis and effects on platelets | Q40113741 | ||
| Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo | Q41261399 | ||
| Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes | Q41429832 | ||
| Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists | Q41452584 | ||
| The multiple complexes formed by the interaction of platelet factor 4 with heparin | Q42165472 | ||
| The activation of prothrombin. II. Partial reactions, physical and chemical characterization of the intermediates of activation. | Q47956980 | ||
| The Purification and Mechanism of Action of Human Antithrombin-Heparin Cofactor | Q47962380 | ||
| Effects of an antithrombotic agent (MD-805) on progressing cerebral thrombosis. | Q54049123 | ||
| Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. | Q54127127 | ||
| Paired analysis of urinary thromboxane B2 metabolites in humans. | Q54367265 | ||
| Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction | Q68123206 | ||
| A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction | Q69175486 | ||
| Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis | Q69224498 | ||
| Activation/inactivation of human factor V by plasmin | Q69292314 | ||
| Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction | Q69740665 | ||
| Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets | Q69871824 | ||
| Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo | Q69889541 | ||
| The role of activated human platelets in prothrombin and factor X activation | Q70048529 | ||
| Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? | Q70265367 | ||
| An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease | Q70304959 | ||
| Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation | Q70376888 | ||
| Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites | Q70875398 | ||
| Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid | Q71255368 | ||
| Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents | Q71281988 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombolysis | Q1931577 |
| plasminogen | Q107129060 | ||
| P304 | page(s) | 7585-7589 | |
| P577 | publication date | 1989-10-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator | |
| P478 | volume | 86 |
| Q40342837 | Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin |
| Q73364963 | Adjunctive Therapy with an Antithrombotic Drug Can Prevent Reocclusion and Induce Residual Thrombus Reduction After Percutaneous Transcatheter Angioplasty of the Thrombotic Lesions |
| Q36864128 | Adjuvant effect of argatroban on staphylokinase induced thrombolysis of platelet rich thrombi in rat mesenteric venules in vivo |
| Q40432300 | Antiplatelet drugs. A comparative review |
| Q33606832 | Antiplatelet therapy--Part I |
| Q41865617 | Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin |
| Q41834459 | Antithrombotic effect of a novel recombinant hirudin analogue, CX-397, in a rat arterial thrombosis model |
| Q42548747 | Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022. |
| Q52314493 | Argatroban During Percutaneous Transluminal Coronary Angioplasty: Results of a Dose-Verification Study. |
| Q73448113 | Argatroban, a thrombin inhibitor, decreased mortality after 10 min of forebrain ischemia in the gerbil |
| Q24561385 | Characterization of a functional thrombin receptor. Issues and opportunities |
| Q34126365 | Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. |
| Q35796005 | Critical review of mouse models of venous thrombosis |
| Q73295856 | Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: A Multicenter Clinical Trial of Argatroban |
| Q42717484 | Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator |
| Q71974401 | Endogenous and Exogenous Nitric Oxide Protect Against Intracoronary Thrombosis and Reocclusion After Thrombolysis |
| Q30843513 | Enhanced endogenous thrombolysis induced by a specific factor Xa inhibitor, DX-9065a, evaluated in a rat arterial thrombolysis model in vivo. |
| Q41082452 | Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase |
| Q67870384 | Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis |
| Q34536091 | Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism |
| Q73302807 | In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist |
| Q73128626 | Inhibition of arterial thrombosis by a peptide ligand of the thrombin receptor |
| Q35805471 | Light-activated protein inhibition through photoinduced electron transfer of a ruthenium(II)-cobalt(III) bimetallic complex |
| Q47339841 | Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries |
| Q30305538 | Management of Acute Ischemic Coronary Syndromes: The Present and Future |
| Q39329081 | Modeling thrombus formation and growth |
| Q40463597 | Novel Antithrombotic Drugs in Development |
| Q71129084 | Pathophysiology of coronary artery disease |
| Q40559317 | Pharmacology of current and future antithrombotic therapies. |
| Q37806238 | Platelets and fibrinolysis |
| Q45058323 | Prediction of Thrombus Growth: Effect of Stenosis and Reynolds Number |
| Q39048394 | Proinflammatory signaling functions of thrombin in cancer. |
| Q71974513 | Role of Thrombin Compared With Factor Xa in the Procoagulant Activity of Whole Blood Clots |
| Q47360550 | Search for an animal model to investigate selective pulmonary vasodilation |
| Q73755199 | Shifts in the affinity distribution of one class of seven-transmembrane receptors by activation of a separate class of seven-transmembrane receptors |
| Q40664734 | Specific thrombin inhibitors in vivo |
| Q34208881 | Systemic lysis protects against the effects of platelet activation during coronary thrombolysis |
| Q41614451 | Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function |
| Q32043322 | The antithrombotic effect of potent bifunctional thrombin inhibitors based on hirudin sequence, P551 and P532, on He-Ne laser-induced thrombosis in rat mesenteric microvessels |
| Q41734671 | The isoprostanes: a perspective |
| Q33392640 | Therapeutic Implications of a Specific Murine Monoclonal Antibody (7E3) to the Platelet Receptor GPIIb/IIIa |
| Q40486965 | Thrombin and antithrombotic therapy in interventional cardiology |
| Q35607594 | Thrombin receptor expression in normal and atherosclerotic human arteries |
| Q37113049 | Thromboxane A2 receptor antagonists |